utcomes for people with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML) are poorer than those for people with many other cancers, but they have continually improved in recent decades for both children 1-3 and adults. 1,4 More intensive chemotherapy for adult patients, stem cell transplantation, and better supportive care have contributed to improved survival. 5 When primary prevention options are limited, as is the case with leukaemia, changes in survival can indicate whether advances in clinical and supportive care are being translated into practice at the population level. 6 Differences in survival gains can indicate disparities in access to improved care associated with remoteness, cultural or language barriers, or socio-economic circumstances. 7 National and regional changes in cancer survival (for all cancers and for selected solid tumours) suggest that differences linked with socio-economic status, place of residence, and ethnic background are increasing in Australia. [8][9][10] Persistent and possibly increasing differences in the survival of patients with acute leukaemia have also been reported overseas, particularly in the United States, 4,[11][12][13] but not in the United Kingdom. 14 Changes in survival for people with acute leukaemia in Australia have not been described in detail.We therefore examined population trends in 5-year survival rates for people in South Australia diagnosed with acute leukaemia during 1980-2016. To assess disparities in access to and provision of care, we focused on changes in disease-specific mortality in different socio-demographic groups.
MethodsThe South Australian Cancer Registry (SACR) supplied deidentified data for our study. The SACR receives statutory notifications of all cancer diagnoses in South Australia (population, 2021: 1.8 million), and captures information on acute leukaemia diagnoses and incidence and survival data, but not detailed treatment information.We included all primary cases of ALL (International Classification of Diseases for Oncology [ICD-O-3] codes M9826, M9835-9837, M9801, M9805, M9820, M9831, M9832, M9833, M9834) and AML (ICD-O-3 codes M9840, M9860, M9861, M9866-9874, M9891-9920, M9930-9931) diagnosed during 1 January 1980 -31 December 2016, and follow-up data to 31 December 2018. We excluded cases of acute undifferentiated leukaemia and mixed phenotype acute leukaemia, myelodysplastic/myeloproliferative neoplasms, and chronic myelomonocytic leukaemia.We extracted information on date of diagnosis (year and month), age at diagnosis, sex, date and cause of death (ICD-10 cancer codes or other record), country of birth (Australia, other Englishspeaking country, non-English-speaking country, missing), residential postcode-based socio-economic status (Index of Relative Socio-Economic Advantage and Disadvantage 15 for 2011; by quintile), and remoteness of residence (Accessibility Remoteness Index of Australia Standard Classification 16 for 2006; metropolitan, inner regional, and outer regional/remote areas). Cause and date of dea...